Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Bayer702 enrolled

Overview

Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.

Study Type

OBSERVATIONAL

Enrollment

702

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

Interferon beta-1b (Betaseron, BAY86-5046)DRUG

Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder

Interferon beta-1b (Betaseron, BAY86-5046)DRUG

Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder

Interferon beta-1b (Betaseron, BAY86-5046)DRUG

Interferon beta-1b (Betaferon)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients with the diagnosis of Multiple Sclerosis and decision by the investigator to prescribe Betaferon.The decision for treatment type and duration is taken before offering the patient the possibility to participate in the study. Exclusion Criteria: * Patients, who do not meet the Clinically Isolated Syndrome (CIS) or Relapsing/Remitting Multiple Sclerosis (RRMS) criteria, should not be included. * Exclusion criteria must be read in conjunction with the German product information.

Locations (1)

Unnamed facility

Many Locations, Germany

Outcomes

Primary Outcomes

Drop out rate over 2 years

Time frame: 24 months